A translational approach to detecting drug-induced cardiac injury with cardiac troponins: Consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute

Brian R. Berridge, Syril Pettit, Dana B. Walker, Alan S. Jaffe, Albert E. Schultze, Eugene Herman, William J. Reagan, Steven E Lipshultz, Fred S. Apple, Malcolm J. York

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Cardiac troponins (cTns) are established biomarkers of ischemic heart disease in humans. However, their value as biomarkers of cardiac injury from causes other than ischemic heart disease is now being explored, particularly in drug development. In a workshop sponsored by the Cardiac Troponin Biomarker Working Group of the Health and Environmental Sciences Institute, preclinical, clinical, and regulatory scientists discussed the application of cTns in their respective environments, issues in translating the preclinical application of cTn to clinical studies, and gaps in our understanding of cTn biology and pathobiology. Evidence indicates that cTns are sensitive and specific biomarkers of cardiac injury from varying causes in both animals and humans. Accordingly, monitoring cTns can help ensure patient safety during the clinical evaluation of new drugs. In addition, preclinical characterization of cardiac risk and cTns as biomarkers of that risk can guide relevant clinical application and interpretation. We summarize here the outcomes of the workshop which included consensus statements, recommendations for further research, and a proposal for a cross-disciplinary group of clinical, regulatory, and drug development scientists to collaborate in such research.

Original languageEnglish
Pages (from-to)21-29
Number of pages9
JournalAmerican Heart Journal
Volume158
Issue number1
DOIs
StatePublished - Jul 1 2009

Fingerprint

Troponin
Environmental Health
Biomarkers
Wounds and Injuries
Pharmaceutical Preparations
Myocardial Ischemia
Education
Drug Evaluation
Patient Safety
Research Design
Research

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

A translational approach to detecting drug-induced cardiac injury with cardiac troponins : Consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute. / Berridge, Brian R.; Pettit, Syril; Walker, Dana B.; Jaffe, Alan S.; Schultze, Albert E.; Herman, Eugene; Reagan, William J.; Lipshultz, Steven E; Apple, Fred S.; York, Malcolm J.

In: American Heart Journal, Vol. 158, No. 1, 01.07.2009, p. 21-29.

Research output: Contribution to journalArticle

Berridge, Brian R. ; Pettit, Syril ; Walker, Dana B. ; Jaffe, Alan S. ; Schultze, Albert E. ; Herman, Eugene ; Reagan, William J. ; Lipshultz, Steven E ; Apple, Fred S. ; York, Malcolm J. / A translational approach to detecting drug-induced cardiac injury with cardiac troponins : Consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute. In: American Heart Journal. 2009 ; Vol. 158, No. 1. pp. 21-29.
@article{6a88df92566f41498f623961e93bc4d7,
title = "A translational approach to detecting drug-induced cardiac injury with cardiac troponins: Consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute",
abstract = "Cardiac troponins (cTns) are established biomarkers of ischemic heart disease in humans. However, their value as biomarkers of cardiac injury from causes other than ischemic heart disease is now being explored, particularly in drug development. In a workshop sponsored by the Cardiac Troponin Biomarker Working Group of the Health and Environmental Sciences Institute, preclinical, clinical, and regulatory scientists discussed the application of cTns in their respective environments, issues in translating the preclinical application of cTn to clinical studies, and gaps in our understanding of cTn biology and pathobiology. Evidence indicates that cTns are sensitive and specific biomarkers of cardiac injury from varying causes in both animals and humans. Accordingly, monitoring cTns can help ensure patient safety during the clinical evaluation of new drugs. In addition, preclinical characterization of cardiac risk and cTns as biomarkers of that risk can guide relevant clinical application and interpretation. We summarize here the outcomes of the workshop which included consensus statements, recommendations for further research, and a proposal for a cross-disciplinary group of clinical, regulatory, and drug development scientists to collaborate in such research.",
author = "Berridge, {Brian R.} and Syril Pettit and Walker, {Dana B.} and Jaffe, {Alan S.} and Schultze, {Albert E.} and Eugene Herman and Reagan, {William J.} and Lipshultz, {Steven E} and Apple, {Fred S.} and York, {Malcolm J.}",
year = "2009",
month = "7",
day = "1",
doi = "10.1016/j.ahj.2009.04.020",
language = "English",
volume = "158",
pages = "21--29",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - A translational approach to detecting drug-induced cardiac injury with cardiac troponins

T2 - Consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute

AU - Berridge, Brian R.

AU - Pettit, Syril

AU - Walker, Dana B.

AU - Jaffe, Alan S.

AU - Schultze, Albert E.

AU - Herman, Eugene

AU - Reagan, William J.

AU - Lipshultz, Steven E

AU - Apple, Fred S.

AU - York, Malcolm J.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Cardiac troponins (cTns) are established biomarkers of ischemic heart disease in humans. However, their value as biomarkers of cardiac injury from causes other than ischemic heart disease is now being explored, particularly in drug development. In a workshop sponsored by the Cardiac Troponin Biomarker Working Group of the Health and Environmental Sciences Institute, preclinical, clinical, and regulatory scientists discussed the application of cTns in their respective environments, issues in translating the preclinical application of cTn to clinical studies, and gaps in our understanding of cTn biology and pathobiology. Evidence indicates that cTns are sensitive and specific biomarkers of cardiac injury from varying causes in both animals and humans. Accordingly, monitoring cTns can help ensure patient safety during the clinical evaluation of new drugs. In addition, preclinical characterization of cardiac risk and cTns as biomarkers of that risk can guide relevant clinical application and interpretation. We summarize here the outcomes of the workshop which included consensus statements, recommendations for further research, and a proposal for a cross-disciplinary group of clinical, regulatory, and drug development scientists to collaborate in such research.

AB - Cardiac troponins (cTns) are established biomarkers of ischemic heart disease in humans. However, their value as biomarkers of cardiac injury from causes other than ischemic heart disease is now being explored, particularly in drug development. In a workshop sponsored by the Cardiac Troponin Biomarker Working Group of the Health and Environmental Sciences Institute, preclinical, clinical, and regulatory scientists discussed the application of cTns in their respective environments, issues in translating the preclinical application of cTn to clinical studies, and gaps in our understanding of cTn biology and pathobiology. Evidence indicates that cTns are sensitive and specific biomarkers of cardiac injury from varying causes in both animals and humans. Accordingly, monitoring cTns can help ensure patient safety during the clinical evaluation of new drugs. In addition, preclinical characterization of cardiac risk and cTns as biomarkers of that risk can guide relevant clinical application and interpretation. We summarize here the outcomes of the workshop which included consensus statements, recommendations for further research, and a proposal for a cross-disciplinary group of clinical, regulatory, and drug development scientists to collaborate in such research.

UR - http://www.scopus.com/inward/record.url?scp=67049088173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67049088173&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2009.04.020

DO - 10.1016/j.ahj.2009.04.020

M3 - Article

C2 - 19540388

AN - SCOPUS:67049088173

VL - 158

SP - 21

EP - 29

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 1

ER -